- Policy
- Bringing 3rd gen monkeypox vaccine to Korea in discussion
- by Lee, Jeong-Hwan Jun 8, 2022 05:56am
- The government announced on the 7th that it has started discussions on the quantity and schedule for bringing a ‘3rd generation monkeypod vaccine’ to Korea with its manufacturer. The authorities decided to accelerate the introduction of this third-generation vaccine with proven efficacy as the number of confirmed cases of monkeypox cont
- Company
- Avodart leads 6th quarter
- by Kim, Jin-Gu Jun 8, 2022 05:56am
- Dutasteride are strong in the domestic hair loss treatment market. Both original and generic recorded higher sales growth than competitive drug Finasteride. According to IQVIA, a pharmaceutical market research firm, on the 2nd, GSK Avodart's sales in the first quarter were 10.7 billion won, up 9% from 9.9 billion won in the first quarter of l
- Company
- Sales of Nexavar fell sharply
- by Jun 8, 2022 05:55am
- Sales of Nexavar, which has dominated the primary treatment market for liver cancer for 10 years, are falling. This is because prices have fallen due to the release of generic products, and the status of the first treatment for liver cancer as a new drug has been shaken. Compared to two years ago, quarterly sales have halved. ◆Tecentriq w
- Policy
- The price gap between Memantine products is more than 2.5x
- by Lee, Tak-Sun Jun 7, 2022 06:04am
- The price difference between Memantine producst was more than 2.5 times. This is because if there are more than 20 generics depending on the price calculation formula, new products are listed at 85% of the lowest price. Memantine preparations have originally had a large price gap between products, but the gap is widening according to this pri
- Company
- Neutropenia drugs' sales affected by their sales partners
- by Chon, Seung-Hyun Jun 7, 2022 06:04am
- GC Pharma and Kyowa Kirin are fiercely competing for the lead in the neutropenia treatment market in Korea. At the end of last year, GC Pharma’s Neulapeg had risen to the lead for the first time in 7 years, but Kyowa Kirin has again taken over the lead with Neulasta. The addition of Boryung’s sales power to the products is affecting the sales
- Company
- Emgality passes DREC review… what about Ajovy?
- by Eo, Yun-Ho Jun 7, 2022 06:04am
- With Emgality nearing insurance reimbursement in Korea, what path Ajovy will walk is also gaining attention. Teva-Handok Pharma had applied for the reimbursement of its calcitonin gene-related peptide (CGRP) targeting migraine drug Ajovy (fremanezumab) earlier this year. However, Ajovy’s reimbursement was not deliberated as an agenda at
- Policy
- Price Negotiation for One-shot Treatment Zolgensma
- by Lee, Tak-Sun Jun 7, 2022 06:04am
- Zolgensma of Novartis, which passed the Drug Reimbursment Evaluation Committee of the HIRA on the 12th of last month, began negotiations on drug prices to register health insurance benefits. Given that Kymriah of the same company, which has attracted attention as a once-in-a-lifetime drug, succeeded in being reimbursed two months after passin
- Company
- Cumulative sales of Spinraza in 3yrs is ₩200 billion
- by Chon, Seung-Hyun Jun 7, 2022 06:03am
- Spinraza, a rare disease treatment, posted 200 billion won in sales over the past three years after registering health insurance benefits. Although there is not much demand, it has achieved high performance in a short period of time due to the nature of expensive treatments worth nearly 100 million won per bottle. According to IQVIA, a pharma
- Company
- Bio USA to be held offline for the first time in 3 years
- by Kim, Jin-Gu Jun 3, 2022 06:37am
- The Bio International Convention (BIO USA),’ which is known as one of the largest global events in the biotechnology industry, is set to be held in San Diego USA from the 13th to the 16th of this month. Twenty or more pharma and bio companies in Korea including Samsung Biologics, Celltrion, SK Pharmteco, and Lotte Biologics are plannin
- Company
- Pharmas succeed in additionally avoiding Entresto patent
- by Kim, Jin-Gu Jun 3, 2022 06:37am
- Domestic pharmaceutical companies have succeeded in additionally avoiding the patent of Novartis’s heart failure treatment ‘Entresto.’ According to industry sources on the 2nd, the Intellectual Property Trial and Appeal Board recently ruled that the claims were established in the trial to confirm the passive scope of rights on Entresto
